The European Medicines Agency has said that booster doses of the Covid-19 vaccine from Pfizer may be considered at least six months after the second dose, for people aged 18 years and older.
It has evaluated data for the Pfizer vaccine in people with normal immune systems, showing a rise in antibody levels when a booster dose is given approximately six months after the second dose, in people from 18 to 55 years old.
The agency said that at national level, public health bodies may issue official recommendations on the use of booster doses, taking into account emerging effectiveness data and the limited safety data.
It said the risk of inflammatory heart conditions, or other very rare side effects after a booster is not known and is being